ENLITE screening lab work goes to Birmingham Women's and Children's
- NHS England
- West Midlands
- 1 bid
NHS England chose Birmingham Women's and Children's NHS Foundation Trust to run newborn screening lab work using the ENLITE methodology.
The work serves the NHS Newborn Blood Spot in-service evaluation for Severe Combined Immuno-Deficiency (SCID), which is adding Spinal Muscular Atrophy (SMA) on the advice of the UK NSC. Lab capacity has to sit alongside existing SCID work. The trust also provides specialist scientific and clinical staff, keeps methods and validation consistent, and handles the secure data flows behind national reporting.
NHS England awarded the work directly in March 2026, at an estimated £110,028. The contract runs for two years, with an option of a third that could take it to March 2029.
- What
- Screening and population testing programmes
- Buyer
- NHS England
- Value
- £110,028
- How it was bought
- Not published
- 1 bid
- Dates and next
- 5 Mar 2026